Feb. 6, 2012
/PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced the appointment of two executive officers, effective immediately.
Andrew I. Koven
has been named Executive Vice President, Chief Administrative Officer and General Counsel, and
Mark A. Glickman
has been named Senior Vice President, Sales.
"The leadership appointments we are announcing today advance our efforts to help position Auxilium for sustainable success and the next stage of its evolution," said
, Chief Executive Officer and President of Auxilium. "Collectively, Andrew and Mark's broad expertise and industry experience should significantly enhance our capabilities as we seek to maximize the value of XIAFLEX® and Testim®, deliver on our current pipeline, and capitalize on future growth opportunities to achieve profitability and drive shareholder value."
Mr. Koven has over 26 years of experience practicing law, most of which has been in the pharmaceutical industry. He most recently served as President and Chief Administrative Officer of Neurologix, Inc. Prior to that, Mr. Koven was Executive Vice President and Chief Administrative and Legal Officer at Inspire Pharmaceuticals, Inc., where he oversaw all matters related to legal, quality and compliance, corporate development and licensing and technical operations prior to the strategic acquisition of the company by Merck & Co. From 2007 to 2010 Mr. Koven served as Executive Vice President, General Counsel and Corporate Secretary at Sepracor Inc. before its acquisition by Dainippon Sumitomo Pharma Co in 2009. Before joining Sepracor, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., where he oversaw the company's legal, compliance and quality assurance departments until the acquisition of the company by Abbott Laboratories in 2006. Mr. Koven began his career in the pharmaceutical industry as an Assistant General Counsel at Warner-Lambert Company from 1993 to 2000, followed by his role as Senior Vice President and General Counsel at Lavipharm Corporation from 2000 to 2003. From 1986 to 1992 he was a corporate associate at Cahill, Gordon & Reindel in
. In his new role, Mr. Koven will be assuming responsibility for the Company's legal functions, government affairs and technical operations.
Mr. Glickman has over 20 years of experience in pharmaceutical sales and operations, with expertise in a variety of fields including sales turnarounds, global product introductions and organizational expansions. Most recently he was Vice President of the medical device division of Otsuka America Pharmaceutical, Inc., a U.S. division of the
-based Otsuka Pharmaceutical Company. At Otsuka, he helped to reinvigorate the company's sales and increase its business by 50% over two years, while also spearheading quality improvement initiatives and playing a critical role in new regulatory filings. Prior to that, he served as Senior Vice President of Sales and Marketing at Oscient Pharmaceuticals Corp., from 2007 to 2009, during which time he completed a successful turnaround of the company's commercial strategy, driving a significant increase in sales during his tenure. Before joining Oscient, Mr. Glickman served as Vice President of Sales at Bayer Healthcare's Diabetes Care Division. From 2001 to 2007 he played a major role in helping to build the commercial organization at Kos Pharmaceuticals by holding various positions including Director of Marketing, Regional Sales Director and Vice President of Sales. Prior to that, he was a Senior Product Manager at Bristol-Myers Squibb, where, during his tenure, he contributed to revenue growth of
The Company also announced the departures of
Jennifer Evans Stacey, Esq.
, the Company's Executive Vice President, General Counsel, and Secretary;
, Senior Vice President, Sales; and
, Executive Vice President, Technical Operations.
"On behalf of the Auxilium Board of Directors and senior management team, I would like to thank Jennifer, Ed, and Edward for their contributions to the Company over the years," continued Mr. Adams. "Each has played an important role in Auxilium's successes and we wish them well in their future endeavors."